Japan has approved a blood test kit to measure Alzheimer’s, which affects millions of individuals worldwide, according to a statement from the manufacturer Sysmex Corporation on Thursday. The company is working to create a kit that is affordable, can detect the accumulation of a protein to treat the disease, and can be introduced to the market as quickly as possible because the current diagnosis is pricy and invasive.
Sysmex has been working on a technique to more easily and rapidly detect the buildup of (amyloid beta) in the brain to address problems with the diagnosis of Alzheimer’s disease, according to the business. Contrary to standard testing approaches, it was claimed, “(the kit) permits testing using blood, decreasing the physical, mental, and financial strain on patients.”
Alzheimer’s is a degenerative illness that robs people of their most precious memories
Alzheimer’s is a degenerative illness that robs people of their most precious memories. Tau and amyloid beta, which accumulate into tangles and plaques and cause brain cell death and brain shrinkage, are two crucial sites for it. The Alzheimer Association, a US-based organization, claimed that if the company is successful, it will revolutionize the way Alzheimer’s and other dementias are diagnosed.
An urgent need for straightforward, affordable, non-invasive, and easily accessible diagnostic methods, such as blood tests to diagnose the condition, was stated. Researchers and medical professionals are striving to create a reliable diagnostic method for the illness. Lecanemab, a medication, was effectively used last month to delay the cognitive loss of Alzheimer’s patients by over 27% over the course of an 18-month experiment. However, the research also indicated that it had negative consequences, such as swelling and brain bleeding.